ConductScience.org, home

Paper39713985

Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.

Yang X and 8 others. Future Med Chem, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges. Papers, record 39713985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39713985

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.
PubMed
Journal
Future Med Chem
PubMed
Year
2025
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-24
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang XXin
2Li XXiang
3Zhang YLYue-Lin
4Zhang SNSheng-Nan
5Zhang MMiao
6Sun CChong
7Yang LLi
8Liu HMHong-Min
9Yuan SShuo

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138637634Targeting KRAS in cancer.Nat Med2024https://conductscience.org/library/papers/38637634PubMed
23915535ras gene Amplification and malignant transformation.Mol Cell Biol1985https://conductscience.org/library/papers/3915535PubMed
335046095Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Cancer Discov2022https://conductscience.org/library/papers/35046095PubMed
438924388Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor.J Med Chem2024https://conductscience.org/library/papers/38924388PubMed
531666701The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature2019https://conductscience.org/library/papers/31666701PubMed
634680208Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers.Cancers (Basel)2021https://conductscience.org/library/papers/34680208PubMed
736849761Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study.J Comput Aided Mol Des2023https://conductscience.org/library/papers/36849761PubMed
839298590Targeting cancer with small-molecule pan-KRAS degraders.Science2024https://conductscience.org/library/papers/39298590PubMed
924256730K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.Nature2013https://conductscience.org/library/papers/24256730PubMed
1038236605Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.Cancer Discov2024https://conductscience.org/library/papers/38236605PubMed
1138009264Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.Med Res Rev2024https://conductscience.org/library/papers/38009264PubMed
1236546659Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.N Engl J Med2023https://conductscience.org/library/papers/36546659PubMed
1337870968Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.N Engl J Med2023https://conductscience.org/library/papers/37870968PubMed
1437395055Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration.J Med Chem2023https://conductscience.org/library/papers/37395055PubMed
1537729426Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.Cancer Res2023https://conductscience.org/library/papers/37729426PubMed
1627338794A combinatorial strategy for treating KRAS-mutant lung cancer.Nature2016https://conductscience.org/library/papers/27338794PubMed
1730481508Clinical validation of coexisting driver mutations in colorectal cancers.Hum Pathol2019https://conductscience.org/library/papers/30481508PubMed
1834365406KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.Clin Cancer Res2021https://conductscience.org/library/papers/34365406PubMed
1935101229Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.Adv Cancer Res2022https://conductscience.org/library/papers/35101229PubMed
2037921024Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors.J Med Chem2023https://conductscience.org/library/papers/37921024PubMed

See all 27 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39713985

GET https://conductscience.org/api/papers/v1/39713985/references?page=2